Churko Chuchu, Yihune Manaye, Teshome Abinet, Chisha Yilma, Getachew Birhanu, Sleshi Markos, Asfaw Mekuria Asnakew, Shibiru Tamiru, Ayele Nebiyu Negussu, Seife Fikre, Zerdo Zerihun, Bekele Kassahun Alemayehu
Collaborative Research and Training Center for Neglected Tropical Diseases, College of Medicine and Health Sciences, Arba Minch University, Arba Minch, Ethiopia.
Department of Public Health, College of Medicine and Health Sciences, Arba Minch University, Arba Minch, Ethiopia.
J Multidiscip Healthc. 2021 Jan 18;14:137-144. doi: 10.2147/JMDH.S288239. eCollection 2021.
Onchocerciasis is the second leading cause of blindness globally next to trachoma, thus eliminating the infection is an important health priority. It is estimated that 15.7 million people are at risk of infection in different parts of Ethiopia. Mass drug administration with ivermectin at community and school level is the basis for control and elimination of onchocerciasis. This study was aimed at validating onchocerciasis treatment coverage in the selected districts of Ethiopia.
A community-based cross-sectional study was employed in Itang special and Wombera districts of Ethiopia, from April 1 to 30, 2019 G.C. We used a coverage validation survey builder tool to compute sample size. Individuals aged five years old and above were eligible population. Data were entered into Microsoft Excel and exported to STATA 14 for cleaning and analyses. A chi-square test was used to note statistical association of the outcome variables with independent variables.
A total of 3765 individuals were interviewed. Of these, 3244 were offered onchocerciasis treatment. The overall treatment coverage of onchocerciasis in the two selected districts of Ethiopia was 85.9% of the eligible population (3235/3765) (95% CI, 84.8%, 87%). There was significant difference between the two districts in terms of ivermectin offering (X=70.467, <0.001). School attendance was also significantly associated with treatment offering and swallowing status (X=77.29, <0.001; and X=30.581, <0.001). The main reported reasons for not being offered ivermectin were "being absent" (40.86%) and "not knowing about the mass drug administration" (MDA) (25.29%).
In conclusion, the treatment coverage of onchocerciasis in this survey was higher than minimum national desired therapeutic coverage. Treatment coverage in Wombera was higher than Itang special district. In addition, children who attended school had a higher chance of swallowing the drug.
盘尾丝虫病是全球仅次于沙眼的第二大致盲原因,因此消除该感染是一项重要的卫生优先事项。据估计,埃塞俄比亚不同地区有1570万人面临感染风险。在社区和学校层面进行伊维菌素群体给药是控制和消除盘尾丝虫病的基础。本研究旨在验证埃塞俄比亚选定地区的盘尾丝虫病治疗覆盖率。
2019年4月1日至30日,在埃塞俄比亚的伊唐特区和翁贝拉区开展了一项基于社区的横断面研究。我们使用覆盖验证调查生成工具来计算样本量。五岁及以上的个体为符合条件的人群。数据录入Microsoft Excel并导出到STATA 14进行清理和分析。使用卡方检验来记录结果变量与自变量之间的统计关联。
共采访了3765人。其中,3244人接受了盘尾丝虫病治疗。埃塞俄比亚这两个选定地区盘尾丝虫病的总体治疗覆盖率为符合条件人群的85.9%(3235/3765)(95%置信区间,84.8%,87%)。在伊维菌素给药方面,两个地区存在显著差异(X=70.467,<0.001)。上学情况也与给药和吞咽情况显著相关(X=77.29,<0.001;X=30.581,<0.001)。未接受伊维菌素治疗的主要报告原因是“缺席”(40.86%)和“不知道群体给药”(25.29%)。
总之,本次调查中盘尾丝虫病的治疗覆盖率高于国家期望的最低治疗覆盖率。翁贝拉区的治疗覆盖率高于伊唐特区。此外,上学的儿童吞咽药物的几率更高。